However, inhibition of BCR::ABL1 tyrosine kinase in Ph + ALL is insufficient to suppress leukemic cell growth and require more comprehensive and potent therapeutic approaches to achieve the eradication of Ph + ALL.44 This could explained the limited response observed in the patient with the p.I293_K294insNAPEA mutation, predominantly treated with dasatinib alone. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.